CARDINAL HEALTH, INC. - 2025 third_quarter

Health Issues

Issues related to drug pricing, bona fide service fees, Affordable Care Act subsidies, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine and issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages (H.R.4299 Protecting Patient Access to Cancer and Complex Therapies Act; H.R.5031 Preserving Patient Access to Long-Term Care Pharmacies Act; H.R.3164/S.2426 Ensuring Community Access to Pharmacist Services Act). Issues related to DMEPOS supplies, competitive bidding, reimbursement to home health agencies, and acute hospital care at home services (H.R.5142 Home Health Stabilization Act of 2025).

Centers For Medicare and Medicaid Services (CMS)Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESSENATE

Manufacturing

View all

Education on supply chain issues, drug shortages, domestic manufacturing, medical device environmental issues; Issues related to the medical supply chain and transportation.

HOUSE OF REPRESENTATIVESSENATE

Trade (domestic/foreign)

View all

Tariff (miscellaneous tariff bills)

View all

Issues related to tariffs, trade, and U.S. trade policy.

Commerce, Dept of (DOC)Food & Drug Administration (FDA)SENATEHOUSE OF REPRESENTATIVESTreasury, Dept ofU.S. Trade Representative (USTR)White House Office

2025 third_quarter Filing

Lobbying Activities (4)

Health Issues

Manufacturing

Trade (domestic/foreign)

Tariff (miscellaneous tariff bills)

Lobbyists (4)